Abstract
Schizophrenia is a complex disease whose biology is not completely understood,
a reality that presents a major hurdle to companies developing new therapies
for schizophrenia. As a result, many companies have focused on the development
of agents that, like existing agents, target the serotonin and dopamine
receptors. Thus, over the next several years, emerging treatments for
schizophrenia are expected to function by the same general mechanisms as
existing therapies. How can they distinguish themselves and gain market share?
What strategies will companies working in this field employ to extend the use
and sales of their agents? What are the prospects for development of agents
that work via novel mechanisms? In this report, we provide an overview of the
disease of schizophrenia and discuss currently available drugs and emerging
therapies in late-stage development. Last, we assess the current competition
as well as market prospects and competitive strategies for these agents.
| 
View Cart
